Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Last trade$17.19
Day change-$0.42 (-2.39%)
Day range$16.79 – $18.10
Volume633,402
Market cap$2.08B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.08B
Price / earnings
—
Price / book
4.58×
Price / sales
—
EV / sales
—
EV / EBITDA
-6.27×
Profitability
Earnings per share
-$2.39
Return on assets
-55.91%
Return on equity
-62.22%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
11.66×
Quick ratio
11.66×
Cash ratio
5.2×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$238.7M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for IMNM, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$4.02M
$2.93M
$2.74M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$4.02M
$2.93M
$2.74M
Selling, general and administrative
$20.86M
$18.25M
$12.95M
$12.09M
$10.95M
$10.04M
$10.69M
$10.45M
Research and development
$69.51M
$59.89M
$46.38M
$60.77M
$49.19M
$40.45M
$36.87M
$75.26M
Total operating expenses
$90.36M
$78.14M
$59.33M
$72.86M
$60.14M
$50.49M
$47.56M
$85.71M
Operating income
-$90.36M
-$78.14M
-$59.33M
-$72.86M
-$60.14M
-$46.48M
-$44.64M
-$82.97M
Interest expense
$0
$0
$0
$2.96M
$0
$0
$0
$2.72M
Income before taxes
-$85.78M
-$73.13M
-$53.84M
-$69.9M
-$57.46M
-$43.4M
-$41.7M
-$80.25M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$85.78M
-$73.13M
-$53.84M
-$69.9M
-$57.46M
-$43.4M
-$41.7M
-$80.25M
Net income attributable to common shareholders
-$85.78M
-$73.13M
-$53.84M
-$69.9M
-$57.46M
-$43.4M
-$41.7M
-$80.25M
EBITDA
-$89.36M
-$77.18M
-$58.73M
-$72.23M
-$59.55M
-$45.84M
-$44.03M
-$82.52M
Basic earnings per share
-$0.76
-$0.65
-$0.48
-$0.74
-$0.65
-$0.50
-$0.52
-$1.28
Diluted earnings per share
-$0.76
-$0.65
-$0.48
-$0.74
-$0.65
-$0.50
-$0.52
-$1.28
Recent news
Company coverage with links to the original publishers.
Immunome Inc. (IMNM) has a mean analyst price target of $35.33, suggesting 74% upside potential from its current $20.31 price. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions over the past 30 days. However, the article cautions that price targets alone should not drive investment decisions, as analysts often set overly optimistic targets due to business incentives.
Jack Higgins, Chief Scientific Officer of Immunome, sold 9,438 shares (30% of his direct holdings) for approximately $204,000 on April 2, 2026, through a pre-arranged Rule 10b5-1 trading plan established in December 2025. The sale represents routine financial diversification rather than a bearish signal, as Higgins maintains a substantial $480,000 direct position. The real catalyst for investors is Immunome's planned NDA submission for varegacestat in Q2 2026, following positive Phase 3 RINGSIDE trial results in December 2025.
In the preceding three months, 4 analysts have released ratings for Immunome (NASDAQ:IMNM), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
3
0
0
0
Last 30D
0
1
0
0
0
1M Ago
0
0
0
0
0
2M Ago
1
2
0
0
0
3M Ago
0
0
0
0
0
Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.75, a high estimate of $35.00, and a low estimate of $24.00. This current average reflects an increase of 10.19% from the previous average price target of $27.00.
Understanding Analyst Ratings: A Comprehensive Breakdown
A comprehensive examination of how financial experts perceive Immunome is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Biren Amin
Piper Sandler
Announces
Overweight
$27.00
-
Brian Cheng
JP Morgan
Announces
Overweight
$24.00
-
Michael Schmidt
Guggenheim
Announces
Buy
$35.00
-
David Nierengarten
Wedbush
Raises
Outperform
$33.00
$27.00
Key Insights:
Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Immunome. This offers insight ...Full story available on Benzinga.com
Immunome (IMNM) delivered earnings and revenue surprises of 57.50% and 74.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Immunome (IMNM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.